Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 50
- Registration Number
- NCT06980116
- Locations
- 🇪🇸
Hospital Fundación Jiménez Diaz, Madrid, Spain
🇪🇸Hospital Universitario HM Sanchinarro, Madrid, Spain
🇬🇧University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)
Recruiting
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) Relapse
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 142
- Registration Number
- NCT06648512
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇫🇮FHRB (Finnish Hematology Registry and Clinical Biobank), Vantaa, Finland
🇩🇪Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie und Onkologie, Berlin, Germany
Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 170
- Registration Number
- NCT05985655
- Locations
- 🇧🇪
Clinique Universitaires Saint-Luc, Brussels, Belgium
🇬🇧The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom
Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05920408
- Locations
- 🇧🇪
CHU Mont-Godinne, Namur, Belgium
🇧🇪Institute Jules Bordet, Brussels, Belgium
🇫🇷Centre Eugene Marquis, Rennes, France
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
Phase 1
Completed
- Conditions
- Oncology
- Interventions
- Drug: EXS21546 Granule in CapsuleDrug: EXS21546 Powder for Oral SuspensionOther: MidazolamOther: Food EffectOther: Placebo Powder for Oral Suspension
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 64
- Registration Number
- NCT04727138
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath